Carisma Therapeutics: Pioneering Macrophage Engineering at H.C. Wainwright Conference

Carisma Therapeutics (Nasdaq: CARM), a leader in macrophage-focused therapeutics, has announced its participation in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. The company's Co-founder and Chief Scientific Officer, Michael Klichinsky, PharmD, PhD, will present at the conference on Tuesday, February 25 at 10:30 am ET. This presentation offers an opportunity for investors and industry professionals to learn more about Carisma's innovative approach to immunotherapy and its promising pipeline.

Carisma's focus on macrophage engineering sets it apart in the competitive landscape of cell therapy and immunotherapy companies. By leveraging advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy, Carisma is developing CAR-Macrophages, a disruptive approach to immunotherapy that addresses key challenges faced by current cell therapies. These engineered macrophages are designed to target and attack cancer cells, offering a unique and promising avenue for cancer treatment.

One of the key advantages of Carisma's approach is the ability of macrophages to actively recruit into tumors, traveling down a chemokine gradient. This allows them to bypass the trafficking challenges faced by T and NK cells, which are often blocked by tumors. Additionally, CAR-Macrophages are locked into an anti-tumor, or M1, phenotype, driving T cell recruitment and immune activation of the tumor. This helps to overcome the immunosuppressive tumor microenvironment that shuts down infiltrating immune cells in other therapies.

Carisma's pipeline includes multiple product candidates targeting various solid tumors and fibrotic diseases. Some of these candidates include:

* CT-0508: A CAR-macrophage therapy in Phase 1 clinical trials for solid tumors, which has shown promising results in terms of safety and efficacy.
* CT-0525: A CAR-monocyte therapy in Phase 1 clinical trials for solid tumors, designed to enhance the body's immune response against cancer.
* CT-1119: A mesothelin-targeted CAR-monocyte therapy in pre-clinical development for advanced mesothelin-positive solid tumors.

Carisma's participation in the H.C. Wainwright conference comes at a time when the company is actively developing and advancing its product pipeline. The presentation by Michael Klichinsky will provide an opportunity for investors and other stakeholders to learn more about the company's recent advancements and future prospects in macrophage-focused therapeutics.



In conclusion, Carisma Therapeutics' focus on macrophage engineering positions it uniquely in the competitive landscape of cell therapy and immunotherapy companies. By addressing key challenges faced by current cell therapies, Carisma's approach offers a promising avenue for cancer treatment. The company's participation in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference provides an opportunity for investors and industry professionals to learn more about Carisma's innovative approach and promising pipeline. As the company continues to advance its product candidates, it has the potential to make a significant impact on the treatment of cancer and other serious diseases.